{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-013083","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.686309+00:00","generated_at":"2026-05-15T04:34:51.389397+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Moleculin's Annamycin extends survival >60% in metastatic pancreatic cancer preclinical models at AACR 2026","bullets":["Median survival 29 days vs 18 days (p=0.0003) in metastatic PDAC models.","Significant tumor volume reduction across multiple PDAC models (p<0.001).","Higher tumor/pancreatic accumulation vs doxorubicin (p<0.0001).","Induced CD8+ and CD4+ T-cell infiltration, suggesting immune activation.","No cardiotoxicity observed; supports Annamycin's differentiated safety profile."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-013083","json":"https://secwatch.observer/filing/0001437749-26-013083.json","markdown":"https://secwatch.observer/filing/0001437749-26-013083.md","text":"https://secwatch.observer/filing/0001437749-26-013083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926013083/0001437749-26-013083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926013083/mbrx20260422_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:34:51.389397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}